Cardiovascular risk, lipids and pregnancy: Preeclampsia and the risk of later life cardiovascular disease

Heart Lung and Circulation

Volumn 23, Issue 3, 2014, Pages 203-212

  Charlton, Francesca ^a   Tooher, Jane ^a   Rye, Kerry Anne ^a   Hennessy, Annemarie ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Hypertension; Lipids; Preeclampsia; Pregnancy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PRAVASTATIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MATERNAL HYPERTENSION; NONHUMAN; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE;

CARDIOVASCULAR DISEASE; HYPERTENSION; LIPIDS; PREECLAMPSIA; PREGNANCY;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIPIDS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME;

EID: 84896732974     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2013.10.087     Document Type: Review

References (106)

1. Agatisa P.K., Ness R.B., Roberts J.M., Costantino J.P., Kuller L.H., McLaughlin M.K. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004, 286:H1389-H1393.
2. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J 2007, 335:974.
3. Adams E.M., Macgillivray I. Long-term effect of preeclampsia on blood-pressure. Lancet 1961, (7217):1373-1375.
4. Chesley L., Annitto J., Cosgrove R. Long-term follow-up study of eclamptic women. Fifth periodic report. Am J Obstet Gynecol 1968, 101:886.
5. Epstein F.H. Late vascular effects of toxemia of pregnancy. N Engl J Med 1964, 271:391.
6. Carleton H., Forsythe A., Flores R. Remote prognosis of preeclampsia in women 25 years old and younger. Am J Obstet Gynecol 1988, 159:156.
7. Nisell H., Lintu H., Lunell N., Möllerström G., Pettersson E. Blood pressure and renal function seven years after pregnancy complicated by hypertension. BJOG 1995, 102:876-881.
8. North R.A., Simmons D., Barnfather D., Upjohn M. What happens to women with preeclampsia? Microalbuminuria and hypertension following preeclampsia. ANZ J Obstet Gynaecol 1996, 36:233-238.
9. Hannaford P., Ferry S., Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 1997, 77:154-158.
10. Hubel C.A., Snaedal S., Ness R.B., Weissfeld L.A., Geirsson R.T., Roberts J.M., et al. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia. BJOG 2000, 107:776-784.
11. Marin R., Gorostidi M., Portal C.G., Sanchez M., Sanchez E., Alvarez J. Long-term prognosis of hypertension in pregnancy. Hypertens Preg 2000, 19:199-209.
12. Irgens H.U., Reisaeter L., Irgens L.M., Lie R.T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. Br Med J 2001, 323(7323):1213-1217.
13. Smith G.C., Pell J.P., Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129290 births. Lancet 2001, 357(9273):2002-2006.
14. Sattar N., Ramsay J., Crawford L., Cheyne H., Greer I.A. Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension 2003, 42:39-42.
15. Wilson B.J., Watson M.S., Prescott G.J., Sunderland S., Campbell D.M., Hannaford P., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br Med J 2003, 326(7394):845.
16. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005, 366(9499):1797-1803.
17. Wikstrom A.K., Haglund B., Olovsson M., Lindeberg S.N. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG 2005, 112:1486-1491.
18. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008, 156:918-930.
19. Lykke J.A., Langhoff-Roos J., Sibai B.M., Funai E.F., Triche E.W., Paidas M.J. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009, 53:944-951.
20. Magnussen E.B., Vatten L.J., Smith G.D., Romundstad P.R. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors [Research Support Non-U.S. Gov't]. Obstet Gynecol 2009, 114:961-970.
21. Garovic V.D., Bailey K.R., Boerwinkle E., Hunt S.C., Weder A.B., Curb D., et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens 2010, 28:826-833.
22. Mongraw-Chaffin M.L., Cirillo P.M., Cohn B.A. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010, 56:166-171.
23. Funai E.F., Friedlander Y., Paltiel O., Tiram E., Xue X., Deutsch L., et al. Long-term mortality after preeclampsia. Epidemiology 2005, 16:206-215.
24. Jonsdottir L.S., Arngrimsson R., Geirsson R.T., Sigvaldason H., Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Obstet Gynecol Surv 1996, 51:390.
25. Kestenbaum B., Seliger S.L., Easterling T.R., Gillen D.L., Critchlow C.W., Stehman-Breen C.O., et al. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis 2003, 42:982-989.
26. Bhattacharya S., Prescott G.J., Iversen L., Campbell D., Smith W.C.S., Hannaford P.C. Hypertensive disorders of pregnancy and future health and mortality: a record linkage study. Pregnancy Hypertens 2012, 2:1-7.
27. Skjærven R., Wilcox A.J., Klungsøyr K., Irgens L.M., Vikse B.E., Vatten L.J., et al. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective population based cohort study. BMJ 2012, 345.
28. Boyd E.M. The lipemia of pregnancy. J Clin Invest 1934, 13(2):347-363.
29. Dieckmann W.J., Wegner C.R. Studies of the blood in normal pregnancy IV. Percentages and grams per kilogram of serum protein and fibrin and variations in total amount of each. Arch Intern Med 1934, 53:540.
30. Hessler J.R., Robertson A.L., Chisolm G.M. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979, 32:213-229.
31. Rye K.A., Bursill C.A., Lambert G., Tabet F., Barter P.J. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009, 50(Suppl.):S195-S200.
32. Barter P.J., Rye K.A. High density lipoprotein cholesterol: the new target. Therapeutic Guides 2007, Sherborne Gibbs Ltd, UK. 3rd ed.
33. Cheung M.C., Albers J.J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984, 259:12201-12209.
34. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
35. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005, 111:1543-1550.
36. Navab M., Reddy S.T., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009, 50(Suppl.):S145-S149.
37. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 2006, 98(11):1352-1364. [Epub 2006/06/10].
38. Tso C., Martinic G., Fan W.H., Rogers C., Rye K.A., Barter P.J. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 2006, 26(5):1144-1149.
39. Potter J.M., Nestel P.J. The hyperlipidemia of pregnancy in normal and complicated pregnancies. Am J Obstet Gynecol 1979, 133(2):165-170.
40. Sattar N., Gaw A., Packard C.J., Greer I.A. Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Br J Obstet Gynaecol 1996, 103:614-620.
41. Alvarez J.J., Montelongo A., Iglesias A., Lasuncion M.A., Herrera E. Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res 1996, 37:299-308.
42. Abbassi-Ghanavati M., Greer L.G., Cunningham F.G. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009, 114:1326-1331.
43. Sattar N., Bendomir A., Berry C., Shepherd J., Greer I.A., Packard C.J. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol 1997, 89:403-408.
44. Kaaja R., Tikkanen M.J., Viinikka L., Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gynecol 1995, 85:353-356.
45. Gratacos E., Casals E., Sanllehy C., Cararach V., Alonso P.L., Fortuny A. Variation in lipid levels during pregnancy in women with different types of hypertension. Acta Obstet Gynecol Scand 1996, 75:896-901.
46. Ogura K., Miyatake T., Fukui O., Nakamura T., Kameda T., Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. J Atheroscler Thromb 2002, 9:42-47.
47. Enquobahrie D.A., Williams M.A., Butler C.L., Frederick I.O., Miller R.S., Luthy D.A. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens 2004, 17:574-581.
48. Gratacos E., Casals E., Gomez O., Llurba E., Mercader I., Cararach V., et al. Increased susceptibility to low density lipoprotein oxidation in women with a history of pre-eclampsia. BJOG 2003, 110:400-404.
49. Lorentzen B., Drevon C.A., Endresen M.J., Henriksen T. Fatty acid pattern of esterified and free fatty acids in sera of women with normal and pre-eclamptic pregnancy. Br J Obstet Gynaecol 1995, 102:530-537.
50. Hubel C.A., McLaughlin M.K., Evans R.W., Hauth B.A., Sims C.J., Roberts J.M. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48hours post partum. Am J Obstet Gynecol 1996, 174(3):975-982.
51. Murai J.T., Muzykanskiy E., Taylor R.N. Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia. Metabolism 1997, 46:963-967.
52. Belo L., Caslake M., Gaffney D., Santos-Silva A., Pereira-Leite L., Quintanilha A., et al. Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis 2002, 162:425-432.
53. Magnussen E.B., Vatten L.J., Lund-Nilsen T.I., Salvesen K.A., Davey Smith G., Romundstad P.R. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007, 335(7627):978.
54. Kandimalla B.H., Sirjusingh A., Nayak B.S., Maiya S.S. Early antenatal serum lipid levels and the risk of pre-eclampsia in Trinidad and Tobago. Arch Physiol Biochem 2011, [Epub 2011/01/14].
55. Lorentzen B., Birkeland K.I., Endresen M.J., Henriksen T. Glucose intolerance in women with preeclampsia. Acta Obstet Gynecol Scand 1998, 77:22-27.
56. Maseki M., Nishigaki I., Hagihara M., Tomoda Y., Yagi K. Lipid peroxide levels and lipids content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. Clin Chim Acta 1981, 115:155-161.
57. Mikhail M.S., Basu J., Palan P.R., Furgiuele J., Romney S.L., Anyaegbunam A. Lipid profile in women with preeclampsia: relationship between plasma triglyceride levels and severity of preeclampsia. J Assoc Acad Minor Phys 1995, 6:43-45.
58. van den Elzen H.J., Wladimiroff J.W., Cohen-Overbeek T.E., de Bruijn A.J., Grobbee D.E. Serum lipids in early pregnancy and risk of pre-eclampsia. Br J Obstet Gynaecol 1996, 103:117-122.
59. Ozan H., Esmer A., Kolsal N., Copur O.U., Ediz B. Plasma ascorbic acid level and erythrocyte fragility in preeclampsia and eclampsia. Eur J Obstet Gynecol Reprod Biol 1997, 71:35-40.
60. Hubel C.A., Lyall F., Weissfeld L., Gandley R.E., Roberts J.M. Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Metabolism 1998, 47:1281-1288.
61. Powers R.W., Evans R.W., Majors A.K., Ojimba J.I., Ness R.B., Crombleholme W.R., et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998, 179(6 Pt 1):1605-1611.
62. Schjetlein R., Abdelnoor M., Haugen G., Husby H., Sandset P.M., Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999, 78:191-197.
63. Khaliq F., Singhal U., Arshad Z., Hossain M.M. Study of serum lipid and lipoprotein in pre-eclampsia with special reference to parity. Indian J Physiol Pharmacol 2000, 44(2):192-196.
64. Clausen T., Djurovic S., Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG 2001, 108(10):1081-1087. [Epub 2001/11/13].
65. Williams M.A., Woelk G.B., King I.B., Jenkins L., Mahomed K. Plasma carotenoids, retinol, tocopherols, and lipoproteins in preeclamptic and normotensive pregnant Zimbabwean women. Am J Hypertens 2003, 16:665-672.
66. Winkler K., Wetzka B., Hoffmann M.M., Friedrich I., Kinner M., Baumstark M.W., et al. Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J Clin Endocrinol Metab 2003, 88:1162-1166.
67. Bayhan G., Kocyigit Y., Atamer A., Atamer Y., Akkus Z. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. Gynecol Endocrinol 2005, 21:1-6.
68. Aziz R., Mahboob T. Pre-eclampsia and lipid profile. Pak J Med Sci 2007, 23:751-754.
69. Wiznitzer A., Mayer A., Novack V., Sheiner E., Gilutz H., Malhotra A., et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009, 201. 482e1-8.
70. Baker A.M., Klein R.L., Moss K.L., Haeri S., Boggess K. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. Am J Obstet Gynecol 2009, 201. 293e1-4.
71. Lima V.J., Andrade C.R., Ruschi G.E., Sass N. Serum lipid levels in pregnancies complicated by preeclampsia. Sao Paulo Med J 2011, 129:73-76.
72. Demir B., Demir S., Atamer Y., Guven S., Atamer A., Kocyigit Y., et al. Serum levels of lipids, lipoproteins and paraoxonase activity in pre-eclampsia. J Int Med Res 2011, 39:1427-1431.
73. Demirci O., Tugrul A.S., Dolgun N., Sozen H., Eren S. Serum lipids level assessed in early pregnancy and risk of pre-eclampsia. J Obstet Gynaecol Res 2011, 37:1427-1432.
74. Pecks U., Caspers R., Schiessl B., Bauerschlag D., Piroth D., Maass N., et al. The evaluation of the oxidative state of low-density lipoproteins in intrauterine growth restriction and preeclampsia. Hypertens Pregnancy 2012, 31:156-165.
75. Bueno A.A., Ghebremeskel K., Bakheit K.H., Elbashir M.I., Adam I. Dimethyl acetals, an indirect marker of the endogenous antioxidant plasmalogen level, are reduced in blood lipids of Sudanese pre-eclamptic subjects whose background diet is high in carbohydrate. J Obstet Gynaecol 2012, 32:241-246.
76. Bukan N., Kandemir O., Nas T., Gulbahar O., Unal A., Cayci B. Maternal cardiac risks in pre-eclamptic patients. J Matern Fetal Neonatal Med 2012, 25:912-914.
77. Zhou J., Zhao X., Wang Z., Hu Y. Combination of lipids and uric acid in mid-second trimester can be used to predict adverse pregnancy outcomes. J Matern Fetal Neonatal Med 2012, [Epub 2012/06/28].
78. Davey D.A., MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988, 158:892-898.
79. Brown M.A., Lindheimer M.D., de Swiet M., Van Assche A., Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001, 20(1):IX-XIV.
80. Lorentzen B., Henriksen T. Plasma lipids and vascular dysfunction in preeclampsia. Semin Reprod Endocrinol 1998, 16:33-39.
81. Parazzini F., Bortolus R., Chatenoud L., Restelli S., Ricci E., Marozio L., et al. Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. Epidemiology 1996, 7:306-308.
82. Sattar N., Greer I.A. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ 2002, 325(7356):157-160.
83. Barden A., Singh R., Walters B., Beilin L.J. Identifying gestation diabetics at 'high risk' for future diabetes from cvd risk factors measured in pregnancy. J Hypertens 2012, 30(e-Suppl. 1):e226.
84. Wadsack C., Tabano S., Maier A., Hiden U., Alvino G., Cozzi V., et al. Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition. Am J Physiol Endocrinol Metab 2007, 292:E476-E484.
85. Catov J.M., Ness R.B., Kip K.E., Olsen J. Risk of early or severe pre-eclampsia related to pre-existing conditions. Int J Epidemiol 2007, 36:412-419.
86. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
87. Kumasawa K., Ikawa M., Kidoya H., Hasuwa H., Saito-Fujita T., Morioka Y., et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011, 108:1451-1455.
88. Williams D., Ahmed A. The StAmP trial: a proof of principle, double-blind, randomised placebo-controlled, multi centre trial of pravastatin to ameliorate early onset pre-eclampsia. Clinical Trial 2012, ISR Clinical Trial Network, UK.
89. Cudmore M., Ahmad S., Al-Ani B., Fujisawa T., Coxall H., Chudasama K., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115(13):1789-1797.
90. Redecha P., van Rooijen N., Torry D., Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009, 113(17):4101-4109.
91. Ardans J.A., Economou A.P., Martinson J.M., Zhou M., Wahl L.M. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol 2002, 71(6):1012-1018.
92. Norata G.D., Pellegatta F., Hamsten A., Catapano A.L., Eriksson P. Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. Int J Mol Med 2003, 12(1):73-78.
93. Lindstedt L., Saarinen J., Kalkkinen N., Welgus H., Kovanen P.T. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem 1999, 274:22627-22634.
94. Narverud I., Halvorsen B., Nenseter M.S., Retterstol K., Yndestad A., Dahl T.B., et al. Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia. J Intern Med 2012, [Epub 2012/08/16].
95. Clay M.A., Pyle D.H., Rye K.A., Vadas M.A., Gamble J.R., Barter P.J. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001, 157:23-29.
96. Roberts J.M., Hubel C.A. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 1999, 354(9181):788-789.
97. Contreras F., Fouillioux C., Bolivar A., Betancourt M.C., Colmenares Y., Rivero M., et al. Endothelium and hypertensive disorders in pregnancy. Am J Ther 2003, 10:415-422.
98. Ness R.B., Roberts J.M. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996, 175:1365-1370.
99. Hamad R.R., Eriksson M.J., Silveira A., Hamsten A., Bremme K. Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy. J Hypertens 2007, 25:2301-2307.
100. Yinon Y., Kingdom J.C., Odutayo A., Moineddin R., Drewlo S., Lai V., et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010, 122:1846-1853.
101. Germain A.M., Romanik M.C., Guerra I., Solari S., Reyes M.S., Johnson R.J., et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?. Hypertension 2007, 49:90-95.
102. Chambers J.C., Fusi L., Malik I.S., Haskard D.O., De Swiet M., Kooner J.S. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001, 285:1607-1612.
103. Poston L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006, 58(Suppl.):69-74.
104. Kramer A., Jansen A.C.M., van Aalst-Cohen E.S., Tanck M.W.T., Kastelein J.J.P., Zwinderman A.H. Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health 2006, 6:262.
105. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
106. Lecarpentier E., Morel O., Fournier T., Elefant E., Chavatte-Palmer P., Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 2012, 72:773-788.